A Study of LY3484356 in Women With Breast Cancer Before Having Surgery (EMBER-2)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.
EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Estimated Study Start Date :
February 8, 2021
Estimated Primary Completion Date :
March 21, 2022
Estimated Study Completion Date :
March 21, 2022
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Gender Based Eligibility:
Accepts Healthy Volunteers:
Have histologically confirmed invasive ER+, HER2- breast carcinoma
Be willing and able to provide pre- and on-treatment tumor samples
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale
Have adequate organ function
Be able to swallow capsules
Participant Must Not:
Have bilateral invasive breast cancer
Have metastatic breast cancer
Plan to receive concurrent neoadjuvant therapy with any other non-protocol anti-cancer therapy
Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer
Have had prior radiotherapy to the ipsilateral chest wall for any malignancy
Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), either for osteoporosis or prevention of breast cancer
Have had prior hormone-replacement therapy within 4 weeks of the start of study treatment
Have had major surgery within 28 days prior to randomization to allow for post-operative healing of the surgical wound and site(s)
Be pregnant or breastfeeding
Have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled